Ablation Devices Market, By Technology Type (Radiofrequency ablation, Cryoablation, Microwave ablation, Ultrasound Ablation, Hydrothermal Ablation, Others), By Application (Cardiovascular Disease, Cancer, Gynecology, Pain Management, Others), By End User (Hospitals, Ambulatory Surgery Centers/Clinics, Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Published In : Feb 2024

Code : CMI464

Pages :305

Formats :

Excel and PDF

Industry : Medical Devices

Market News

Recent Developments

On December 13. 2023, Medtronic, a medical device company, announced that the U.S. Food and Drug Administration (FDA) had approved the PulseSelect Pulsed Field Ablation (PFA) System for the treatment of both paroxysmal and persistent atrial fibrillation (AF). The PulseSelect PFA system was engineered with differentiated safety features and provides rapid, effective pulmonary vein isolation (PVI) through consistent and predictable energy delivery and catheter maneuverability.

On May 19, 2023, Abbott, announced that the U.S. Food and Drug Administration (FDA) had approved the company's TactiFlex Ablation Catheter, Sensor Enabled, the world's first ablation catheter with a flexible tip and contact force technology. Used to perform an ablation procedure to treat atrial fibrillation (AFib), the most common abnormal heart rhythm, the TactiFlex catheter can result in reduced procedure times and better safety.
In April 2021, Medtronic received breakthrough device designation status from the U.S. Food and Drug Administration (FDA) for the Emprint ablation catheter kit – an investigational device not yet approved or cleared in the U.S.

Acquisition and partnerships

On November 17, 2023, Boston Scientific Corporation, a health care company, announced the close of its acquisition of Relievant Medsystems Inc., a company that offers the only U.S. Food and Drug Administration-cleared Intracept Intraosseous Nerve Ablation System, a therapy to treat vertebrogenic pain that is a form of chronic low back pain. The Intracept system, a basivertebral nerve ablation therapy, will be an addition to the Boston Scientific chronic pain portfolio that includes spinal cord stimulation, radiofrequency ablation, and an interspinous spacer procedure.
In December 2021, BD, a medical technology company, announced that it had acquired Venclose, Inc., a provider of solutions for the treatment of chronic venous insufficiency, a disease that is the result of malfunctioning valves and can lead to varicose veins. Venclose is a leader in CVI treatment through its innovative Radio Frequency (RF) ablation technology platform designed for versatility, efficiency, and simplicity.